No Data
No Data
JW (Cayman) Therapeutics Co. Ltd's (HKG:2126) Shares Leap 26% Yet They're Still Not Telling The Full Story
JW (Cayman) Therapeutics Co. Ltd (HKG:2126) shares have had a really impressive month, gaining 26% after a shaky period beforehand. Unfortunately, the gains of the last month did little to right th
Changes in Hong Kong stocks | Pharmaceutical Juno-B (02126) rose more than 8%, SLE clinical data showed good safety
Pharmaceutical Juno-B (02126) rose more than 8%. As of press release, it had risen 8.29% to HK$2.35, with a turnover of HK$2,041,800.
Preliminary Clinical Data on Relma-Cel Injection in Adults With Active Systemic Lupus Erythematosus in China at the Eular 2024 Congress
SHANGHAI, May 30, 2024 /PRNewswire/ -- JW (Cayman) Therapeutics Co. Ltd (the "Company" or "JW Therapeutics", together with its subsidiaries, the "Group"), an independent and innovative biotechnology c
JW (Cayman) Therapeutics Presents Trial Data From SLE Drug at Rheumatology Congress
JW (Cayman) Therapeutics (HKG:2126) presented the preliminary clinical data on its relmacabtagene autoleucel injection trial for adults in China at the 2024 European Alliance of Associations for Rheum
Pharmaceutical Junuo (02126) announced the latest data on rekiolense injections at the European Congress of Rheumatology
Jinwu Financial News | Yao Ming Junuo (02126) announced that the latest clinical data on rekiolense injection in Chinese adults with active systemic lupus erythematosus was announced at the 2024 European Congress of Rheumatology (EULAR 2024). Rickie Orense (oncology indication trade name Benoda) has been approved by China's State Drug Administration for two indications, including treatment of recurrent or refractory large B-cell lymphoma in adult patients after second-line or above systematic treatment, and treatment of refractory follicular lymphoma in adults with second-line or higher systemic treatment or recurrent within 24 months, became
Medication Junol-B (02126.HK): Preliminary clinical data on rekiolense injection for the treatment of active systemic lupus erythematosus in adult Chinese patients with active systemic lupus erythematosus announced in EULAR 2024
On May 30, Gelonghui | Pharmacomingjuno-B (02126.HK) announced the latest clinical data on patients with active systemic lupus erythematosus (“SLE”) in Chinese adults with active systemic lupus erythematosus (“SLE”) at the 2024 European Congress of Rheumatology (“EULAR 2024”). According to disclosure, systemic lupus erythematosus is a chronic autoimmune disease that causes damage to multiple organs and tissues throughout the body. According to estimates, there are about 1 million people with systemic lupus erythematosus in China, ranking first in the world in total number and second in incidence. Currently traditional treatments for systemic lupus erythematosus include cortical
No Data